Abstract:This review article summarizes the relevant English literature on gout from 2010 through April 2017. It emphasizes that the current epidemiology of gout indicates a rising prevalence worldwide, not only in Western countries but also in Southeast Asia, in close relationship with the obesity and metabolic syndrome epidemics. New pathogenic mechanisms of chronic hyperuricaemia focus on the gut (microbiota, ABCG2 expression) after the kidney. Cardiovascular and renal comorbidities are the key points to consider in terms of management. New imaging tools are available, including US with key features and dual-energy CT rendering it able to reveal deposits of urate crystals. These deposits are now included in new diagnostic and classification criteria. Overall, half of the patients with gout are readily treated with allopurinol, the recommended xanthine oxidase inhibitor (XOI), with prophylaxis for flares with low-dose daily colchicine. The main management issues are related to patient adherence, because gout patients have the lowest rate of medication possession ratio at 1 year, but they also include clinical inertia by physicians, meaning XOI dosage is not titrated according to regular serum uric acid level measurements for targeting serum uric acid levels for uncomplicated (6.0 mg/dl) and complicated gout, or the British Society for Rheumatology recommended target (5.0 mg/dl). Difficult-to-treat gout encompasses polyarticular flares, and mostly patients with comorbidities, renal or heart failure, leading to contraindications or side effects of standard-of-care drugs (colchicine, NSAIDs, oral steroids) for flares; and tophaceous and/or destructive arthropathies, leading to switching between XOIs (febuxostat) or to combining XOI and uricosurics.

Full attension to standardization of the diagnosis and treatment of gout and hyperuricemia

The Role of Advanced Imaging in Gout Management

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases

The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

Hyperuricemia and its related diseases: mechanisms and advances in therapy

[Gout, beyond the joint: How should we treat it?]

[Modern understanding of uric acid metabolism disorders and progress in traditional Chinese medicine prevention and treatment]

Progress in Treatment of Gout Using Chinese and Western Medicine

The Therapeutic Management of Chemical and Herbal Medications on Uric Acid Levels and Gout: Modern and Traditional Wisdom

Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions

Advances in the Study of Hyperuricemia and Gout

Physiology of Hyperuricemia and Urate-Lowering Treatments

Update of concepts and recommendations on the treatment for gout in 2016

Diagnosis, treatment, and prevention of gout

Gout: state of the art after a decade of developments

Diagnosis and treatment of asymptomatic hyperuricemia

Gout and Diet: A Comprehensive Review of Mechanisms and Management

A Review of Uric Acid, Crystal Deposition Disease, and Gout

The role of diet in gout and hyperuricemia

Controversies and practical management of patients with gout and chronic kidney disease